Andrographis (AP-Bio) Clinical Evidence
Saxena RC, et al. A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection. 2010 Mar;17(3-4):178-85.
Can a proprietary extract of andrographis (previously KalmCold, now AP-Bio) help relieve symptoms of upper respiratory tract infections?
Andrographis has long been used in Ayurvedic medicine to stimulate the immune system and to reduce inflammation.
Human clinical intervention trial
Randomized, double-blind, placebo-controlled. Subjects took either AP-Bio andrographis extract or placebo and rated the following symptoms: cough, expectoration, nasal discharge, headache, fever, sore throat, earache, malaise/fatigue, and sleep disturbance.
200 mg/day for 5 days
In both the treatment and placebo groups, symptoms declined from days 1 to 3 of treatment. However, from days 3 to 5, symptoms of subjects in the placebo group stayed the same or worsened, while symptoms of those in the treatment group improved. Overall, AP-Bio was found to be significantly more effective (52.7%) as placebo at reducing symptoms of upper respiratory tract infections.
“The findings of this study revealed that KalmCold [AP-Bio] was effective in reducing symptoms of upper respiratory tract infection.”
Mechanism of Action
Andrographis paniculata (AP-Bio) stimulates the production of protective antibodies and prompts delayed-type hypersensitivity response (a kind of immune response in which T cells and T helper cells recognize an antigen and destroy it on contact). It also spurs the body’s innate (or non-specific) immune response, as measured by increases in proliferation of lymphocytes (a kind of white blood cell) and phagocytosis (a process in which immune cells engulf infectious agents).